Specific Trials Information
| Region | Disease Site | Study ID | Brief Description | MDT Handbook |
|---|---|---|---|---|
| Leeds | Urology | 111 Trial (formerly BEP 111) | A single arm multi-centre study evaluating a single cycle of BEP as adjuvant chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours |  Leeds Urology |
| Leeds | Liver | ABC-03 | Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin/gemcitabine chemotherapy for patients with advanced biliary tract cancers | Leeds Liver |
| Leeds | Haematology | ADMIRE | Does the addition of mitoxantrone improve response? A randomised phase II trial of fludarabine, cyclophosphamide and rituximab mitoxantrone in previously untreated CLL | Leeds Haematology |
| Calderdale & Huddersfield | Haematology | ADMIRE | Does the addition of mitoxantrone improve response? A randomised phase II trial of fludarabine, cyclophosphamide and rituximab mitoxantrone in previously untreated CLL. | C&H Haematology |
| Leeds | Gynaecology | Advocate | Advanced Ovarian Cancer: Care and Treatment Experiences | Leeds Gynaecology |
| Leeds | Breast | AFFECT | Examination of affected tissue of BRCA1 variant carriers | Leeds Breast |
| Leeds | Paediatrics | ALLR3 | An International Collaborative Trial for relapsed Refractory Acute Lymphoblastic Leukaemia (ALL) | Leeds Paediatrics |
| York | Haematology | AML 17 | Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17 | York Haematology |
| Mid Yorkshire | Haematology | AML 17 | Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17 | Mid Yorkshire Haematology |
| Leeds | Haematology | AML 17 | Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17 | Leeds Haematology |
| Bradford | Haematology | AML 17 | Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17 | Bradford Haematology |
| Leeds | Haematology | AML 18 Pilot | A Phase 1B/2 Study to Evaluate the Feasibility of combining either the Tyrosine kinase Inhibitor AC220, or the CXCR4 inhibitor Plerixafor with Chemotherapy in older patients with Acute Myeloid Leukaemia and Myelodysplastic Syndrome in patients over 60 yea | Leeds Haematology |
| Leeds | Haematology | ARCTIC | A randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR) | Leeds Haematology |
| Harrogate | Haematology | ARCTIC | A randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR) | Harrogate Haematology |
| Mid Yorkshire | Haematology | ARCTIC | A randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR) | Mid Yorkshire Haematology |
| Bradford | Colorectal | Aristotle | A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer | Bradford Colorectal |
| York | Colorectal | Aristotle | A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer | York Colorectal |
| Leeds | Colorectal | Aristotle | A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer | Leeds Colorectal |
| Airedale | Colorectal | Aristotle | A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer | Airedale Colorectal |
| Calderdale & Huddersfield | Colorectal | Aristotle | A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer | C&H Colorectal |
| Mid Yorkshire | Colorectal | Aristotle | A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer | Mid Yorkshire Colorectal |
| Leeds | Head & Neck | ART DECO | A Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs Standard Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and Hypopharyngeal Cancers. | Leeds Head & Neck |
| York | Head & Neck | ART DECO | A Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs Standard Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and Hypopharyngeal Cancers. | York Head & Neck |
| Leeds | Breast | ARTemis | Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer. | Leeds Breast |
| Leeds | Paediatrics | AT9283 in children and adolescents with acute leukemia | A Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hours every 21 days via intravenous infusion in children and adolescents aged 6 months to 18 years with relapsed and refractory acute leukaemia | Leeds Paediatrics |
| Leeds | Skin | AVAST-M | Adjuvant aVAStin Trial in high risk Melanoma - A randomised trial evaluating the VEGF inhibitor, bevacizumab (Avastin®),as adjuvant therapy following resection of AJCC stage IIB (T3bN0M0 & T4aN0M0), IIC (T4bN0M0) and III (TxN1-3M0) cutaneous melanoma | Melanoma/Skin |
| Leeds | Liver | BILCAP | A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer | Leeds Liver |
| Calderdale & Huddersfield | Upper GI | BILCAP | A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer | C&H Upper GI |
| Mid Yorkshire | Urology | BOXIT | BOXIT | Mid Yorkshire Urology |
| Calderdale & Huddersfield | Urology | BOXIT | BOXIT | C&H Urology |
| Leeds | Urology | BOXIT | BOXIT | Leeds Urology |
| Leeds | Breast | Breast cancer, sexuality and intimacy | A semi structured interview study to explore the sexual problems experienced by women diagnosed with breast cancer and to examine the support services available to help women manage sexual problems | Leeds Breast |
| Leeds | Haematology | CHOP-OR | Single arm NCRI feasibility study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s Syndrome | Leeds Haematology |
| Mid Yorkshire | Upper GI | ChOPIN | Chemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia (IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic assessment independent | Mid Yorkshire Upper GI |
| York | Upper GI | ChOPIN | Chemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia (IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic assessment independent | York Upper GI |
| Harrogate | Upper GI | ChOPIN | Chemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia (IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic assessment independent | Harrogate Upper GI |
| Leeds | Gynaecology | CIRCCa | Cediranib In Recurrent Cervical Cancer - A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer | Leeds Gynaecology |
| Leeds | Haematology | CLEAR | A phase II trial of broad spectrum antibiotic therapy for early stage, non-progressive chronic lymphocytic leukaemia without adverse prognostic factors | Leeds Haematology |
| Leeds | Paediatrics | CNS 2004 03 | Cooperative Multicentre Study For Children And Adolescents With Low Grade Glioma (CNS 2004 03) | Leeds Paediatrics |
| Bradford | Lung | CONVERT | A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status | Bradford Lung |
| Leeds | Lung | CONVERT | A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status | Leeds Lung |
| Harrogate | Lung | CONVERT | A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status | Harrogate Lung |
| Leeds | Breast | COPE | Diagnostic and therapeutic insights into breast cancer from morphological and molecular profiling of breast tumours in patients with germline p53 mutations (Li Fraumeni Syndrome) | Leeds Breast |
| Leeds | Head and Neck | CoSTAR | COchlear Sparing Therapy And conventional Radiation: A Multicentre Randomised Study Of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Parotid Tumours | Leeds Head & Neck |
| Bradford | Colorectal | CReST | The role of endoluminal stenting in the acute management of obstructing colorectal cancer | Bradford Colorectal |
| Harrogate | Colorectal | CReST | The role of endoluminal stenting in the acute management of obstructing colorectal cancer | Harrogate Colorectal |
| Leeds | Colorectal | CReST | The role of endoluminal stenting in the acute management of obstructing colorectal cancer | Leeds Colorectal |
| Mid Yorkshire | Colorectal | CReST | The role of endoluminal stenting in the acute management of obstructing colorectal cancer | Mid Yorkshire Colorectal |
| Leeds | Paediatrics | CRUK/CCLG AT9283 in Paediatric Patients | A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours. | Leeds Paediatrics |
| Leeds | Breast | CR UK Stratified Medicine Pilot Study | The Cancer Research UK Stratified Medicine Programme: Pilot Study | Leeds Breast |
| Leeds | Skin | CR UK Stratified Medicine Pilot Study | The Cancer Research UK Stratified Medicine Programme: Pilot Study | Melanoma/Skin |
| Leeds | Gynaecology | CR UK Stratified Medicine Pilot Study | The Cancer Research UK Stratified Medicine Programme: Pilot Study | Leeds Gynaecology |
| Leeds | Haematology | DEC-MDS | Use of Decitabine in Myelodysplastic Syndromes (MDS) Following Azacitidine (AZA) Failure | Leeds Haematology |
| Bradford | Gynaecology | DNA Methylation Study | DNA Methylation as a predictor for response and progression free survival in patients with ovarian cancer | Bradford Gynaecology |
| Leeds | Gynaecology | DNA Methylation Study | DNA Methylation as a predictor for response and progression free survival in patients with ovarian cancer | Leeds Gynaecology |
| Bradford | Haematology | EBV associated NK/T cell malignancies | Study of EBV associated NK/T cell diseases and formation of a registry | Bradford Haematology |
| Leeds | Haematology | EBV associated NK/T cell malignancies | Study of EBV associated NK/T cell diseases and formation of a registry | Leeds Haematology |
| Leeds | Breast | EMBRACE | Epidemiological study of BRCA1 and BRCA2 mutation carriers | Leeds Breast |
| Mid Yorkshire | Breast | EPHOS-B | Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study – Biological phase | Mid Yorkshire Breast |
| Leeds | Breast | EPHOS-B | Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study – Biological phase | Leeds Breast |
| Leeds | Paediatrics | EPOC Docorubicin in children | Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia | Leeds Paediatrics |
| Leeds | Pancreas | ESPAC-Tplus | ESPAC-Tplus Translational Studies (Tissue sample collection from ESPAC Adjuvant Trials in Pancreatic Cancer) | Leeds Pancreas |
| Calderdale & Huddersfield | Upper GI | ESPAC 4 | EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancer | C&H Upper GI |
| Bradford | Upper GI | ESPAC 4 | EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancer | Bradford Upper GI |
| Leeds | Pancreas | ESPAC 4 | EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancer | Leeds Pancreas |
| Leeds | Paediatrics | EsPhALL | European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib | Leeds Paediatrics |
| Leeds | Paediatrics | ET 2000 03 | European Ewing Tumour Working Initiatives of National Groups: Ewing Tumour Studies 1999 | Leeds Paediatrics |
| Calderdale & Huddersfield | Lung | ET Trial | A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer | C&H Lung |
| Leeds | Paediatrics | EuroNet PHL-C1 Hodgkin's | First International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents | Leeds Paediatrics |
| Leeds | Urology | European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast | European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy | Leeds Urology |
| Bradford | Urology | European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast | European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy | Bradford Urology |
| Leeds | Urology | Evaluation of Biomarkers for Prognosis of Renal Cell Carcinoma | Evaluation of Biomarkers for Prognosis and Monitoring in Patients with Renal Cell Carcinoma | Leeds Urology |
| Bradford | Breast | Exploring the needs of breast cancer survivors after treatment | Exploring the emotional, social and functional needs of women living with breast cancer following hospital based treatment: A study to identify unmet needs across different ethnic groups and socioeconomic backgrounds: Version One. | Bradford Breast |
| Leeds | Paediatrics | FACT study | Factors associated with Childhood Tumours Study | Leeds Paediatrics |
| Leeds | Breast | FBCS | Identification and molecular analyses of families with susceptibility to breast cancer | Leeds Breast |
| Airedale | Breast | FH02 | Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02) | Airedale Breast |
| Leeds | Breast | FH02 | Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02) | Leeds Breast |
| Bradford | Breast | FH02 | Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02) | Bradford Breast |
| Leeds | Colorectal | Follow up to MOSAIC study | A non-interventional follow-up to the MOSAIC study (multicenter international study of oxaliplatin/5- Fluorouracil/leucovorin in the adjuvant treatment of colon cancer) up to 10 years, and translational research | Leeds Colorectal |
| Leeds | Colorectal | FOXFIRE | An open-label randomised phase III trial 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio- Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer | Leeds Colorectal |
| Calderdale & Huddersfield | Colorectal | FOxTROT | Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. | C&H Colorectal |
| Leeds | Colorectal | FOxTROT | Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. | Leeds Colorectal |
| Harrogate | Colorectal | FOxTROT | Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. | Harrogate Colorectal |
| York | Colorectal | FOxTROT | Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. | York Colorectal |
| Mid Yorkshire | Colorectal | FOxTROT | Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. | Mid Yorkshire Colorectal |
| Bradford | Colorectal | FOxTROT | Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. | Bradford Colorectal |
| Leeds | Paediatrics | GeDDiS | A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas | Leeds Paediatrics |
| Leeds | Gynaecology | GROINSS-V II | GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II | Leeds Gynaecology |
| York | Head & Neck | HeadandNeck5000 | Evaluation of centralisation in head and neck cancer | York Head & Neck |
| Leeds | Head & Neck | HeadandNeck5000 | Evaluation of centralisation in head and neck cancer | Leeds Head & Neck |
| Leeds | Head and Neck | HopOn | HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomised Controlled Trial of Hyperbaric Oxygen to prevent Osteoradionecrosis of the Irradiated Mandible | Leeds Head & Neck |
| Bradford | Head & Neck | HopOn | HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomised Controlled Trial of Hyperbaric Oxygen to prevent Osteoradionecrosis of the Irradiated Mandible | Bradford Head & Neck |
| Bradford | Urology | HOT II | Randomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | Bradford Urology |
| Leeds | Urology | HOT II | Randomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | Leeds Urology |
| York | Breast | ICICLE | A study to Investigate the genetiCs of In situ Carcinoma of the ductaL subtypE | York Breast |
| Airedale | Gynaecology | ICON 8 | ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard threeweekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovari | Airedale Gynaecology |
| Calderdale & Huddersfield | Gynaecology | ICON 8 | ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard threeweekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovari | C&H Gynaecology |
| Bradford | Gynaecology | ICON 8 | ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard threeweekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovari | Bradford Gynaecology |
| Leeds | Haematology | IELSG 26 | A clinico-pathologic study of Primary Mediastinal B-cell lymphoma | Leeds Haematology |
| Bradford | Breast | IMPORT HIGH | Randomised trial testing dose escalated intensity modulated radiotherapy in women with higher than average local tumour recurrence risk after breast conservation surgery and appropriate systemic therapy for early breast cancer | Bradford Breast |
| Leeds | Breast | IMPORT HIGH | Randomised trial testing dose escalated intensity modulated radiotherapy in women with higher than average local tumour recurrence risk after breast conservation surgery and appropriate systemic therapy for early breast cancer | Leeds Breast |
| Leeds | Haematology | Intestinal t-cell trial (ITCL) | A phase II evaluation of high dose chemotherapy and autologous bone marrow transplantation for intestinal T cell lymphomas | Leeds Haematology |
| Leeds | Upper GI | Irvalec | Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esopha | Leeds Upper GI |
| Leeds | Upper GI | Irvalec® in Metastatic or Advanced Gastric/Esophageal cancer v. 1.0 | Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esopha | Leeds Upper GI |
| Leeds | Urology | LaMB | LaMB – a phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer | Leeds Urology |
| Calderdale & Huddersfield | Urology | LaMB | LaMB – a phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer | C&H Urology |
| Calderdale & Huddersfield | Breast | LANTERN | A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ERb B2 positive metastatic br | C&H Breast |
| Leeds | Breast | LANTERN | A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ERb B2 positive metastatic br | Leeds Breast |
| Airedale | Breast | LATTE | Long-term Anatrozole vs. Tamoxifen Treatment Effects | Airedale Breast |
| Leeds | Breast | LATTE | Long-term Anatrozole vs. Tamoxifen Treatment Effects | Leeds Breast |
| Calderdale & Huddersfield | Breast | LATTE | Long-term Anatrozole vs. Tamoxifen Treatment Effects | C&H Breast |
| Bradford | Breast | LATTE | Long-term Anatrozole vs. Tamoxifen Treatment Effects | Bradford Breast |
| York | Breast | LATTE | Long-term Anatrozole vs. Tamoxifen Treatment Effects | York Breast |
| Leeds | Paediatrics | LEG 2004 06 | Study to investigate lung function following pulmonary radiotherapy in Wilms tumour survivors (LEG 2004 06) | Leeds Paediatrics |
| Leeds | Haematology | LenaRIC | Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma | Leeds Haematology |
| Bradford | Haematology | LI-1 | Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial | Bradford Haematology |
| Airedale | Haematology | LI-1 | Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial | Airedale Haematology |
| Bradford | Head & Neck | LIHNCS | A prospective, multi-centre, randomised controlled trial looking at the effectiveness of Lugol's Iodine to assist excision of marginal dysplasia at resection of oral and oropharyngeal squamous cell carcinoma. | Bradford Head & Neck |
| York | Head & Neck | LIHNCS | A prospective, multi-centre, randomised controlled trial looking at the effectiveness of Lugol's Iodine to assist excision of marginal dysplasia at resection of oral and oropharyngeal squamous cell carcinoma. | York Head & Neck |
| Leeds | Paediatrics | LK 2006 10 | International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia | Leeds Paediatrics |
| Leeds | Lung | LungCAST | Does smoking status after being diagnoses with lung cancer influence outcome? An observational cohort study alongisde a randomised trial of different smoking cessation interventions | Leeds Lung |
| Calderdale & Huddersfield | Lung | LungCAST | Does smoking status after being diagnoses with lung cancer influence outcome? An observational cohort study alongisde a randomised trial of different smoking cessation interventions | C&H Lung |
| Mid Yorkshire | Lung | MALCS | A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women | Mid Yorkshire Lung |
| Airedale | Lung | MALCS | A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women | Airedale Lung |
| York | Lung | MALCS | A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women | York Lung |
| Leeds | Lung | MALCS | A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women | Leeds Lung |
| Harrogate | Lung | MALCS | A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women | Harrogate Lung |
| Calderdale & Huddersfield | Lung | MALCS | A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women | C&H Lung |
| Leeds | Haematology | MARALL | Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent or refractory B-precursor acute lymphoblastic leukaemia (ALL) | Leeds Haematology |
| Calderdale & Huddersfield | Haematology | MDS BIO | Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis | C&H Haematology |
| Leeds | Haematology | MDS BIO | Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis | Leeds Haematology |
| Airedale | Skin | Melanoma Cohort Study | The Melanoma Follow-Up and Case-Control Family Study | Melanoma/Skin |
| York | Skin | Melanoma Cohort Study | The Melanoma Follow-Up and Case-Control Family Study | Melanoma/Skin |
| Harrogate | Skin | Melanoma Cohort Study | The Melanoma Follow-Up and Case-Control Family Study | Melanoma/Skin |
| Bradford | Skin | Melanoma Cohort Study | The Melanoma Follow-Up and Case-Control Family Study | Melanoma/Skin |
| Leeds | Skin | Melanoma Cohort Study | The Melanoma Follow-Up and Case-Control Family Study | Melanoma/Skin |
| Calderdale & Huddersfield | Skin | Melanoma Cohort Study | The Melanoma Follow-Up and Case-Control Family Study | Melanoma/Skin |
| Leeds | Gynaecology | mEOC | A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer | Leeds Gynaecology |
| Leeds | Haematology | MiniAllo | Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma | Leeds Haematology |
| Mid Yorkshire | Haematology | Myeloma XI | Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide | Mid Yorkshire Haematology |
| Harrogate | Haematology | Myeloma XI | Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide | Harrogate Haematology |
| Calderdale & Huddersfield | Haematology | Myeloma XI | Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide | C&H Haematology |
| York | Haematology | Myeloma XI | Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide | York Haematology |
| Leeds | Haematology | Myeloma XI | Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide | Leeds Haematology |
| Bradford | Haematology | Myeloma XI | Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide | Bradford Haematology |
| Leeds | Haematology | Myeloma X Relapse | A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high-dose chemotherapy and autologous stem cell rescue. | Leeds Haematology |
| Mid Yorkshire | Haematology | Myeloma X Relapse | A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high-dose chemotherapy and autologous stem cell rescue. | Mid Yorkshire Haematology |
| Bradford | Haematology | Myeloma X Relapse | A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high-dose chemotherapy and autologous stem cell rescue. | Leeds Haematology |
| Leeds | Paediatrics | NB 2002 06 | High Risk Neuroblastoma Study 1 of SIOP-Europe | Leeds Paediatrics |
| Leeds | Haematology | NCRN069 ORCHARRD | Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL | Leeds Haematology |
| Leeds | Breast | NCRN113 D-CARE | A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE) | Leeds Breast |
| Leeds | Haematology | NCRN132 | An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma | Leeds Haematology |
| Leeds | Haematology | NCRN133 (TELESTO) | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload (Telesto) | Leeds Haematology |
| Calderdale & Huddersfield | Breast | NCRN155 - ISICA | International Study of Incident Cancer (ISICA) - breast cancer and diabetes | C&H Breast |
| Leeds | Haematology | NCRN171 | AL YPMHASPEH 2O/3 MMUALTICENTER, RANDOMIZED OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | Leeds Haematology |
| Calderdale & Huddersfield | Breast | NCRN186 ALTERNATIVE | A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-line therapy in postmenopausal subjects with hormone receptor positive, | C&H Breast |
| Leeds | Haematology | NCRN188 | Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care (The RESPONSE Trial) | Leeds Haematology |
| Leeds | Urology | NCRN211 - IMPRINT | A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma | Leeds Urology |
| Leeds | Haematology | NCRN237 | ORpeelna-lpabseel,d M Aulnti-dce Rnteerf,r saincgtleo-arrym M stuMdy for the safety and efficacy of Pomalidomide (CC-4047) Monotherapy for Subjects with Refractory or Relapsed and Refractory Multiple Myeloma | Leeds Haematology |
| Leeds | Paediatrics | NCRN244 | A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma | Leeds Paediatrics |
| Leeds | Haematology | NCRN246 GALLIUM | AG Ma1ul0tic1e nOterr ,R Pihtausex I imi, Oapiennt-Leanbeal,n Rcanedomized Study In Previously Untreated Patients With Advanced Indolent Non- Hodgkin's Lymphoma Comparing Ga101 (Ro5072759) Plus Chemotherapy With Rituximab Plus Chemotherapy Followed By Ga101 Or Rituximab Maintenance | Leeds Haematology |
| Leeds | Breast | NCRN250 APHINITY | AC aprospective, randomized multicenter, multinational, two-arm comparison of chemotherapy plus trastuzumab given for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant therapy in patients | Leeds Breast |
| Leeds | Paediatrics | NCRN251 | OEppeenn-ladbyelm, Pohamsea 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205 | Leeds Paediatrics |
| Leeds | Haematology | NCRN253 | AA Plkhayslea 2t iSntugd yA tgo eAnsstesss the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents | Leeds Haematology |
| Leeds | Paediatrics | NCRN259 HERBY | A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma | Leeds Paediatrics |
| Leeds | Pancreas | NCRN287 | Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer | Leeds Pancreas |
| Leeds | Haematology | NCRN289 JAKARTA | A Phase 3, Randomized, Double-Blinded, Placebo Controlled 3 arm Study of SAR302503 in Patients with Intermediate-2 or High Risk Primary (PMF), Post Polycythemia Vera (post PV-MF), or Post-Essential Thrombocythemia Myelofibrosis (post ET-MF) with Splenomeg | Leeds Haematology |
| Leeds | Breast | NeoExcel | Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer | Leeds Breast |
| Mid Yorkshire | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | Mid Yorkshire Colorectal |
| Leeds | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | Leeds Colorectal |
| Airedale | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | Airedale Colorectal |
| Calderdale & Huddersfield | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | C&H Colorectal |
| Bradford | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | Bradford Colorectal |
| Harrogate | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | Harrogate Colorectal |
| York | Colorectal | NSCCG | National Study of Colorectal Cancer Genetics | York Colorectal |
| Harrogate | Haematology | NSHLG | National Study of Hodgkin's Lymphoma Genetics | Harrogate Haematology |
| Airedale | Haematology | NSHLG | National Study of Hodgkin's Lymphoma Genetics | Airedale Haematology |
| Bradford | Haematology | NSHLG | National Study of Hodgkin's Lymphoma Genetics | Bradford Haematology |
| Leeds | Haematology | NSHLG | National Study of Hodgkin's Lymphoma Genetics | Leeds Haematology |
| Mid Yorkshire | Haematology | NSHLG | National Study of Hodgkin's Lymphoma Genetics | Mid Yorkshire Haematology |
| York | Haematology | NSHLG | National Study of Hodgkin's Lymphoma Genetics | York Haematology |
| Leeds | Haematology | Ofatumumab Study | Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractoy Mantle Cell Lymphoma | Leeds Haematology |
| Leeds | Paediatrics | OTIS | A Phase II Study to determine the efficacy and safety of conventional dose Oral Treosulfan In patients with advanced pretreated Ewing's Sarcoma | Leeds Paediatrics |
| Mid Yorkshire | Haematology | PACIFICO | Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO) | Mid Yorkshire Haematology |
| Leeds | Haematology | PACIFICO | Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO) | Leeds Haematology |
| Bradford | Haematology | PACIFICO | Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO) | Bradford Haematology |
| Harrogate | Haematology | PACIFICO | Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO) | Harrogate Haematology |
| York | Haematology | PACIFICO | Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO) | York Haematology |
| Calderdale & Huddersfield | Haematology | PACIFICO | Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO) | C&H Haematology |
| Leeds | Haematology | PADIMAC | Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC) | Leeds Haematology |
| Leeds | Paediatrics | PAETR | PAETR Paediatric Trial Recruitment. Optimising recruitment to clinical trials in childhood cancer: perspectives of families and clinicians. | Leeds Paediatrics |
| Leeds | Haematology | PAIRed | PAIReD (Pilot of Allogenic Immunotherapy in Refractory Disease): Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma | Leeds Haematology |
| Leeds | Gynaecology | PARP (BRCA) | A Cancer Research UK Phase II Proof of Principle Trial of the activity of the intravenous PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breast or advanced ovarian cancer | Leeds Gynaecology |
| Leeds | Urology | PATCH | Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer | Leeds Urology |
| Mid Yorkshire | Urology | PATCH | Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer | Mid Yorkshire Urology |
| Calderdale & Huddersfield | Urology | PATCH | Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer | C&H Urology |
| Leeds | Urology | PEPC | Experiences of penile cancer: understanding and improving patients’ experiences after treatment for penile cancer | Leeds Urology |
| Bradford | Breast | Persephone | Duration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelve | Bradford Breast |
| Airedale | Breast | Persephone | Duration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelve | Airedale Breast |
| Bradford | Head & Neck | PET-NECK | A multicentre randomised phase III trial comparing PET-CT guided watch and wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer | Bradford Head & Neck |
| Leeds | Head and Neck | PET-NECK | A multicentre randomised phase III trial comparing PET-CT guided watch and wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer | Leeds Head & Neck |
| Leeds | Pancreas | PET-PANC | The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer. | Leeds Pancreas |
| Leeds | Gynaecology | PETROC/OV21 | A Phase II/III study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin plus Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy | Leeds Gynaecology |
| Leeds | Paediatrics | PK 2006 07 (ActD in children) | Pharmacokinetics of actinomycin D in children with cancer | Leeds Paediatrics |
| Leeds | Paediatrics | PK 2006 09 (Infant PK) | Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young children | Leeds Paediatrics |
| Calderdale and Huddersfield | Haematology | Place of care and death in haematological malignancy | Exploration of factors associated with place of care and place of death in patients with haematological malignancies | C&H Haematologytarget=”_blank”>Calderdale & Huddersfield Haematology |
| Mid Yorkshire | Haematology | Place of care and death in haematological malignancy | Exploration of factors associated with place of care and place of death in patients with haematological malignancies | Mid Yorkshire Haematology |
| York | Haematology | Place of care and death in haematological malignancy | Exploration of factors associated with place of care and place of death in patients with haematological malignancies | York Haematology |
| Harrogate | Haematology | Place of care and death in haematological malignancy | Exploration of factors associated with place of care and place of death in patients with haematological malignancies | Harrogate Haematology |
| Bradford | Haematology | Place of care and death in haematological malignancy | Exploration of factors associated with place of care and place of death in patients with haematological malignancies | Bradford Haematology |
| Leeds | Haematology | Place of care and death in haematological malignancy | Exploration of factors associated with place of care and place of death in patients with haematological malignancies | Leeds Haematology |
| Calderdale & Huddersfield | Breast | POETIC | Trial of Perioperative Endocrine Therapy - Individualising Care | C&H Breast |
| Leeds | Breast | POETIC | Trial of Perioperative Endocrine Therapy - Individualising Care | Leeds Breast |
| Harrogate | Breast | POETIC | Trial of Perioperative Endocrine Therapy - Individualising Care | Harrogate Breast |
| Mid Yorkshire | Breast | POETIC | Trial of Perioperative Endocrine Therapy - Individualising Care | Mid Yorkshire Breast |
| Bradford | Breast | POETIC | Trial of Perioperative Endocrine Therapy - Individualising Care | Bradford Breast |
| Airedale | Breast | POETIC | Trial of Perioperative Endocrine Therapy - Individualising Care | Airedale Breast |
| Leeds | Colorectal | PROSPECT | Icmapnrocveinrg the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography | Leeds Colorectal |
| Bradford | Colorectal | PROSPECT | Icmapnrocveinrg the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography | Bradford Colorectal |
| York | Colorectal | PROSPECT | Icmapnrocveinrg the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography | York Colorectal |
| Calderdale & Huddersfield | Haematology | PT1 (MRC) | A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thrombocythaemia | C&H Haematology |
| Harrogate | Haematology | PT1 (MRC) | A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thrombocythaemia | Harrogate Haematology |
| Mid Yorkshire | Haematology | PT1 (MRC) | A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thrombocythaemia | Mid Yorkshire Haematology |
| Bradford | Haematology | PT1 (MRC) | A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thrombocythaemia | Bradford Haematology |
| Leeds | Haematology | PT1 (MRC) | A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thrombocythaemia | Leeds Haematology |
| Airedale | Haematology | PT1 (MRC) | A Randomised Trial to compare Aspirin versus Hydroxyurea/Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thrombocythaemia | Airedale Haematology |
| Leeds | Colorectal | PulMICC | Pulmonary Metastasectomy in Colorectal Cancer. A Randomised feasibility study of Pulmonary Metastasectomy in Colorectal Cancer | Leeds Colorectal |
| Leeds | Urology | Quality of life of long-term survivors of testicular cancer | Methods and measures for assessing quality of life of mid- to long-term survivors of testicular and prostate cancer from EORTC Phase III Clinical Trials | Leeds Urology |
| Harrogate | Lung | QUARTZ | A phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of pati | Harrogate Lung |
| Calderdale & Huddersfield | Lung | QUARTZ | A phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of pati | C&H Lung |
| Mid Yorkshire | Lung | QUARTZ | A phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of pati | Mid Yorkshire Lung |
| Leeds | Lung | QUARTZ | A phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of pati | Leeds Lung |
| Calderdale & Hudderfield | Breast | QUEST Trial A | A multi-centre randomised trial to assess the impact of the type of breast reconstruction on quality of life of women following mastectomy for early breast cancer | C&H Breast |
| Leeds | Breast | QUEST Trial A | A multi-centre randomised trial to assess the impact of the type of breast reconstruction on quality of life of women following mastectomy for early breast cancer | Leeds Breast |
| York | Breast | QUEST Trial A | A multi-centre randomised trial to assess the impact of the type of breast reconstruction on quality of life of women following mastectomy for early breast cancer | York Breast |
| Leeds | Breast | QUEST Trial B | A multi-centre randomised trial to assess the impact of the timing of breast reconstruction on quality of life of women following mastectomy for early breast cancer | Leeds Breast |
| Calderdale & Huddersfield | Breast | QUEST Trial B | A multi-centre randomised trial to assess the impact of the timing of breast reconstruction on quality of life of women following mastectomy for early breast cancer | C&H Breast |
| York | Breast | QUEST Trial B | A multi-centre randomised trial to assess the impact of the timing of breast reconstruction on quality of life of women following mastectomy for early breast cancer | York Breast |
| Leeds | Haematology | R-CODOX-M/IVAC for DLBCL | A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High-Intermediate Risk | Leeds Haematology |
| Bradford | Haematology | R-CODOX-M/IVAC for DLBCL | A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High-Intermediate Risk | Bradford Haematology |
| Mid Yorkshire | Haematology | R-CODOX-M/IVAC for DLBCL | A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High-Intermediate Risk | Mid Yorkshire Haematology |
| Leeds | Urology | RADICALS (MRC PR10) | Radiotherapy and Androgen Deprivation In Combination After Local Surgery | Leeds Urology |
| York | Urology | RADICALS (MRC PR10) | Radiotherapy and Androgen Deprivation In Combination After Local Surgery | York Urology |
| Bradford | Urology | RADICALS (MRC PR10) | Radiotherapy and Androgen Deprivation In Combination After Local Surgery | Bradford Urology |
| Airedale | Urology | RADICALS (MRC PR10) | Radiotherapy and Androgen Deprivation In Combination After Local Surgery | Airedale Urology |
| Mid Yorkshire | Urology | RADICALS (MRC PR10) | Radiotherapy and Androgen Deprivation In Combination After Local Surgery | Mid Yorkshire Urology |
| Mid Yorkshire | Urology | RAPPER | Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy | Mid Yorkshire Urology |
| Leeds | Urology | RAPPER | Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy | Leeds Urology |
| Bradford | Urology | RAPPER | Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy | Bradford Urology |
| York | Haematology | RATHL | A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphoma | York Haematology |
| Mid Yorkshire | Haematology | RATHL | A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphoma | Mid Yorkshire Haematology |
| Calderdale & Huddersfield | Haematology | RATHL | A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphoma | C&H Haematology |
| Leeds | Haematology | RATHL | A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphoma | Leeds Haematology |
| Leeds | Haematology | ReACH | ReACH (Reduced Intensity Allografting for Chemosensitive Hodgkin Lymphoma): Phase II study of reduced intensity sibling allogeneic transplantation for relapsed, chemosensitive, PET positive Hodgkin lymphoma | Leeds Haematology |
| Airedale | Breast | REACT | A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients | Airedale Breast |
| Bradford | Haematology | REMoDLB | A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib | Bradford Haematology |
| Leeds | Haematology | REMoDLB | A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib | Leeds Haematology |
| Harrogate | Haematology | REMoDLB | A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib | Harrogate Haematology |
| Airedale | Lung | ReSoLuCENT | Resource for the Study of Lung Cancer Epidemiology in North Trent | Airedale Lung |
| Leeds | Lung | REST | A Randomised Trial on Chest Irradiation in Extensive Disease Small Cell Lung Cancer (ED-SCLC | Leeds Lung |
| Leeds | Haematology | RIC UCBT | Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a reduced intensity conditioning regimen | Leeds Haematology |
| Leeds | Colorectal | ROLARR | An international multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer | Leeds Colorectal |
| Calderdale & Huddersfield | Gynaecology | RT3 VIN | A Randomised Trial of Topical Treatment in Women with Vulval Intraepithelial Neoplasia | C&H Gynaecology |
| Leeds | Gynaecology | RT3 VIN | A Randomised Trial of Topical Treatment in Women with Vulval Intraepithelial Neoplasia | Leeds Gynaecology |
| Leeds | Gynaecology | SaPPrOC | A randomised placebo-controlled trial of Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian, fallopian tube or primary peritoneal cancer | Leeds Gynaecology |
| Bradford | Colorectal | SCOT | Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups | Bradford Colorectal |
| York | Colorectal | SCOT | Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups | York Colorectal |
| Airedale | Colorectal | SCOT | Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups | Airedale Colorectal |
| Leeds | Colorectal | SCOT | Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups | Leeds Colorectal |
| Harrogate | Colorectal | SCOT | Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups | Harrogate Colorectal |
| Leeds | Urology | SORCE | A phase III Randomised Controlled Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse | Leeds Urology |
| York | Haematology | SPIRIT 2 | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leuk | York Haematology |
| Harrogate | Haematology | SPIRIT 2 | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leuk | Harrogate Haematology |
| Mid Yorkshire | Haematology | SPIRIT 2 | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leuk | Mid Yorkshire Haematology |
| Bradford | Haematology | SPIRIT 2 | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leuk | Bradford Haematology |
| Airedale | Haematology | SPIRIT 2 | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leuk | Airedale Haematology |
| Leeds | Haematology | SPIRIT 2 | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leuk | Leeds Haematology |
| Leeds | Upper GI | ST03 | A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal Junction | Leeds Upper GI |
| Bradford | Upper GI | ST03 | A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal Junction | Bradford Upper GI |
| Airedale | Upper GI | ST03 | A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal Junction | Airedale Upper GI |
| Calderdale & Huddersfield | Upper GI | ST03 | A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal Junction | C&H Upper GI |
| Calderdale & Huddersfield | Urology | STAMPEDE | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | C&H Urology |
| Leeds | Urology | STAMPEDE | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | Leeds Urology |
| Airedale | Urology | STAMPEDE | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | Airedale Urology |
| Bradford | Urology | STAMPEDE | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | Bradford Urology |
| Leeds | Urology | STAR | STAR: A Randomised MultiStage Phase II/III trial of Sunitinib comparing Temporary cessation with Allowing continuation, at the time of maximal radiological response, in the firstline treatment of locally advanced and/or metastatic Renal cancer | Leeds Urology |
| Leeds | Paediatrics | STS 2006 03 (NRSTS) | EpSSG NRSTS 2005 - A protocol for localised non-rhabdomyosarcoma soft tissue sarcomas | Leeds Paediatrics |
| Leeds | Paediatrics | STS 2006 04 RMS 2005 | EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma (European Paediatric Soft Tissue Sarcoma Study Group) | Leeds Paediatrics |
| Leeds | Urology | SUCCINT | A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advanced transitional carcinoma of the urothelium. | Leeds Urology |
| Mid Yorkshire | Breast | SUPREMO | Selective use of postmastectomy radiotherapy after mastectomy | Mid Yorkshire Breast |
| Leeds | Breast | SUPREMO | Selective use of postmastectomy radiotherapy after mastectomy | Leeds Breast |
| Leeds | Urology | Surtime - EORTC 30073 | EORTC 30073 Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma. | Leeds Urology |
| Leeds | Haematology | The Causes of Clonal Blood Cell Disorders (Adults) | The Causes of Clonal Blood Cell Disorders | Leeds Haematology |
| Leeds | Paediatrics | The Causes of Clonal Blood Disorders | The Causes of Clonal Blood Cell Disorders | Leeds Paediatrics |
| Airedale | Skin | The Melanoma Lifestyle Study | The Melanoma Lifestyle Study | Melanoma/Skin |
| Harrogate | Skin | The Melanoma Lifestyle Study | The Melanoma Lifestyle Study | Melanoma/Skin |
| Leeds | Skin | The Melanoma Lifestyle Study | The Melanoma Lifestyle Study | Melanoma/Skin |
| Mid Yorkshire | Colorectal | The seAFOod Polyp Prevention Trial | A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish O | Mid Yorkshire Colorectal |
| Bradford | Colorectal | The seAFOod Polyp Prevention Trial | A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish O | Bradford Colorectal |
| York | Colorectal | The seAFOod Polyp Prevention Trial | A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish O | York Colorectal |
| Airedale | Colorectal | The seAFOod Polyp Prevention Trial | A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish O | Airedale Colorectal |
| Leeds | Urology | The UK Genetics of Testicular Cancer Study | Identification of testicular germ cell tumour susceptibility genes | Leeds Urology |
| Leeds | Urology | The UK Genetics of Testicular Cancer Study | Identification of testicular germ cell tumour susceptibility genes | Leeds Urology |
| Leeds | Lung | TIME3 | Adjuvant Urokinase in the Treatment of Malignant Pleural Effusion: The Third Therapeutic Intervention in Malignant Effusion Trial (TIME3-UK). (A Randomised Controlled Trial to evaluate whether use of intrapleural Urokinase aids the drainage of multi-septa | Leeds Lung |
| Leeds | Lung | TIPS | THE INHALED PARTICLES STUDY | Leeds Lung |
| Airedale | Breast | TNT | Triple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR-and HER2- or known BRCA1 or BRCA2 mutation associated breast cancer. | Airedale Breast |
| Leeds | Breast | TNT | Triple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA2 mutation associated breast cancer. | Leeds Breast |
| Bradford | Breast | TNT | Triple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA2 mutation associated breast cancer. | Bradford Breast |
| Calderdale & Huddersfield | Urology | TOUCAN | Vandetanib in non-cisplatin fit patients with urothelial cancers -A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatin | C&H Urology |
| Leeds | Urology | TOUCAN | Vandetanib in non-cisplatin fit patients with urothelial cancers -A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatin | Leeds Urology |
| Leeds | Paediatrics | TRANSCAL | Translational Study for Children and Adolescents with Low Grade Glioma | Leeds Paediatrics |
| Leeds | Urology | TRANSORCE | A study to collect blood and tissue samples from consenting patients who have been diagnosed with renal cell cancer. | Leeds Urology |
| Bradford | Colorectal | TREC | Transanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal Cancer | Bradford Colorectal |
| Leeds | Colorectal | TREC | Transanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal Cancer | Leeds Colorectal |
| Leeds | Urology | TRISST (MRC TE24) | Trial of imaging and schedule in seminoma testis | Leeds Urology |
| Mid Yorkshire | Haematology | UKALL 14 | A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia | Mid Yorkshire Haematology |
| Leeds | Haematology | UKALL 14 | A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia | Leeds Haematology |
| Leeds | Haematology | UKALL 2011 | A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia | Leeds Haematology |
| Bradford | Haematology | UKALL 14 | A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia | Bradford Haematology |
| Leeds | Paediatrics | UKALL 2011 | United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011 | Leeds Paediatrics |
| Harrogate | Urology | UK GPCS | UK Genetic Prostate Cancer Study | Harrogate Urology |
| Leeds | Urology | UK GPCS | UK Genetic Prostate Cancer Study | Leeds Urology |
| York | Urology | UK GPCS | UK Genetic Prostate Cancer Study | York Urology |
| Mid Yorkshire | Urology | UK GPCS | UK Genetic Prostate Cancer Study | Mid Yorkshire Urology |
| Calderdale & Huddersfield | Urology | UK GPCS | UK Genetic Prostate Cancer Study | C&H Urology |
| Bradford | Urology | UK GPCS | UK Genetic Prostate Cancer Study | Bradford Urology |
| Airedale | Urology | UK GPCS | UK Genetic Prostate Cancer Study | Airedale Urology |
Disclaimer: The Yorkshire Cancer Research Network make every reasonable effort to ensure that all information provided by us is accurate at the time of its inclusion. From time to time there may be errors, inaccuracies or omissions and we cannot accept liability for these. Whilst we can make available information about clinical trials we cannot facilitate the recruitment of patients on to trials. Although we provide links to other websites we are unable to accept responsibility for their content or any resources linked to this website; neither can we endorse their content, products or services.